SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction-Reference-Cited by-同舟云学术

SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction

Published:2024-01 Issue:1 Volume:12 Page:67-78
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Avula Vennela,Sharma Garima,Kosiborod Mikhail N.,Vaduganathan Muthiah,Neilan Tomas G.,Lopez Teresa^ORCID,Dent Susan,Baldassarre Lauren,Scherrer-Crosbie Marielle,Barac Ana^ORCID,Liu Jennifer,Deswal Anita^ORCID,Khadke Sumanth,Yang Eric H.^ORCID,Ky Bonnie,Lenihan Daniel^ORCID,Nohria Anju^ORCID,Dani Sourbha S.,Ganatra Sarju

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference33 articles.

1. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus;Hsia;Curr Opin Endocrinol Diabetes Obes,2017

2. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019

3. Cardiovascular and renal outcomes with empagliflozin in heart failure;Packer;N Engl J Med,2020

4. Empagliflozin in heart failure with a preserved ejection fraction;Anker;N Engl J Med,2021

5. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial;Chandra;J Am Coll Cardiol HF,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

2. Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling;Current Issues in Molecular Biology;2024-08-31

3. GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors;JACC: Heart Failure;2024-08

4. Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation;Current Treatment Options in Oncology;2024-07-25

5. Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients;Future Cardiology;2024-07-04